Third Harmonic Bio is braving the frosty IPO waters. With the weakest quarter for biotech IPOs in years still fresh in the memory, and the proceeds of a $105 million series B still in its bank account ...
Third Harmonic Bio discontinuing its chronic inducible urticaria program after its only asset failed in a phase 1 safety trial paralyzes its clinical pipeline. Shareholders are now waiting on a ...
On Tuesday, Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD) stock rating was downgraded by Morgan Stanley (NYSE:MS) from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback